Current Industry Pressures on Drug Manufacturer Operations

This whitepaper discusses the current pressures faced by pharmaceutical manufacturers, particularly focusing on the operational challenges stemming from financial constraints and regulatory changes. The Inflation Reduction Act (IRA) has introduced new drug pricing provisions that increase scrutiny on duplicate discounts, leading to revenue loss and operational disruptions. Historically, operations teams prioritized efficiency and timely invoice payments, often at the expense of accuracy, resulting in expected revenue leakage. However, as financial pressures mount, there is a shift towards addressing these inefficiencies. The paper outlines the need for operations teams to adapt their workflows to not only improve efficiency but also to recover lost revenue. It highlights the complexities of managing drug discount programs, particularly the challenges of identifying noncompliant discounts within mandated timeframes. The report emphasizes the importance of evolving strategies to mitigate revenue leakage and enhance the overall financial health of drug manufacturers amidst growing industry challenges.